Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FELDENE SUMMARY NDA DATA WILL BE DISCLOSED, FDA

Executive Summary

FELDENE SUMMARY NDA DATA WILL BE DISCLOSED, FDA told Pfizer attorney William Vodra (D.C. firm Arnold & Porter) in a June 27 letter. FDA Associate Commissioner for Public Affairs Jack Martin stated: "We do not agree that to be considered 'summary,' data must be presented so generally as to be of no assistance in evaluating the safety or effectiveness of a drug. Data may be presented in sufficient detail to allow for evaluation and analysis, yet still be considered 'summary' for purposes of deciding whether they may be disclosed" under Freedom of Information. He said that in his judgment "the data at issue are not so detailed as to be considered something other than a summary of safety and effectiveness data." FDA's letter responded to a Pfizer petition requesting that FDA reconsider its decision allowing public access to certain data submitted to the Feldene NDA in March. Pfizer maintained that the information FDA regarded as publicly releasable summary data could allow competing firms to obtain regulatory approval of identical compounds in foreign countries. FDA reiterated that the information Pfizer seeks to withhold "is presented in summary fashion and is of the type routinely disclosed in accordance with FDA's Freedom of Information Act (FoI) regulations." Indeed, the agency stated, "many of the summaries in question are described under headings bearing the word 'studies,' and merely aggregate summaries of data from more than one study and do not reflect the result of one study or provide raw data on individual patients." The agency asserted that "the summary data Pfizer has submitted cannot be disaggregated to reveal individual study data" and is therefore not exempt from disclosure. FDA further stated that whether or not a record is exempt from disclosure under Exemption 4 of the FoI Act "depends on whether there is a showing of substantial harm to the competitive position of the person from whom the information is being obtained." FDA said Pfizer's claims "do not meet this standard."

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

MT142464

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel